Investment Analysts’ Recent Ratings Changes for Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (NASDAQ: ALNY) has recently received a number of price target changes and ratings updates:

  • 10/8/2018 – Alnylam Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Although we are pleased with Alnylam’s broad and promising pipeline, we note that most candidates are in their early or mid stages of development. These candidates still have a long way to go before hitting the market. Currently, Alnylam depends heavily on Onpattro for growth. We also note that gaining approval for pipeline candidates has become more difficult now.  However,  In August, Alnylam got a significant boost with the approval of Onpattro (patisiran), a first-of-its-kind RNA interference (RNAi) therapeutic, both in the United States and in Europe, for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. This is the first approved candidate for the company and hence should drive revenues. Loss estimates have remained stable ahead of the Q3 earnings release.”
  • 10/1/2018 – Alnylam Pharmaceuticals is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating and a $135.00 price target on the stock. They wrote, “: We are initiating coverage of Overweight rating and a target price of $135. Alnylam is a platform company that develops medicines using their RNA interference technology. We believe that Alnylam is at a key turning point in their history. They are launching their first commercial product and we are bullish about the potential. They have many late stage programs that could bring 4 more drugs to market over the next 2 years including givosiran, lumasiran, inclisiran, and fitusiran .””
  • 9/28/2018 – Alnylam Pharmaceuticals had its price target lowered by analysts at Morgan Stanley from $93.00 to $87.00. They now have an “equal weight” rating on the stock.
  • 9/26/2018 – Alnylam Pharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 9/21/2018 – Alnylam Pharmaceuticals was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.
  • 9/13/2018 – Alnylam Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 9/13/2018 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $152.00 price target on the stock. They wrote, “Alnylam is expected to announce results of an interim analysis of the Phase 3 trial of givosiran in Acute Hepatic Porphyrias (AHP) later this month. The FDA has reportedly indicated that a statistically significant reduction in biomarker urine ALA level w/ the first 30 enrolled patients may be sufficient for accelerated approval. We expect a positive outcome based on strength of data collected from Phase 1/2 testing, in which profound and durable reductions in urine ALA levels were observed. Mgmt has guided for NDA submission by YE18. We assume U.S. commercial launch in 2H19 and WW peak sales $600-700M. Reiterate BUY.””
  • 9/13/2018 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $117.00 price target on the stock, down previously from $123.00.
  • 9/4/2018 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Cowen Inc. They now have a $147.00 price target on the stock.
  • 8/28/2018 – Alnylam Pharmaceuticals was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.
  • 8/28/2018 – Alnylam Pharmaceuticals was given a new $198.00 price target on by analysts at JMP Securities. They now have a “buy” rating on the stock.
  • 8/27/2018 – Alnylam Pharmaceuticals was given a new $152.00 price target on by analysts at Needham & Company LLC. They now have a “buy” rating on the stock.
  • 8/23/2018 – Alnylam Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 8/13/2018 – Alnylam Pharmaceuticals had its price target lowered by analysts at Nomura from $86.00 to $73.00. They now have a “reduce” rating on the stock.
  • 8/13/2018 – Alnylam Pharmaceuticals had its price target lowered by analysts at Cowen Inc from $157.00 to $147.00. They now have an “outperform” rating on the stock.
  • 8/13/2018 – Alnylam Pharmaceuticals had its price target lowered by analysts at BMO Capital Markets from $127.00 to $125.00. They now have an “outperform” rating on the stock.
  • 8/13/2018 – Alnylam Pharmaceuticals was given a new $93.00 price target on by analysts at Morgan Stanley. They now have a “hold” rating on the stock.
  • 8/13/2018 – Alnylam Pharmaceuticals had its price target raised by analysts at B. Riley from $210.00 to $230.00. They now have a “buy” rating on the stock.
  • 8/13/2018 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $152.00 price target on the stock. They wrote, “Alnylam and the FDA announced Friday the approval of Onpattro for the treatment of polyneuropathy caused by hATTR. Mgmt guided for drug to be available today. WAC price is $450,000/yr and mgmt estimates average net price $345,000/yr. Because the label is focused on polyneuropathy, we assume penetration of the PN (only polyneuropathy symptoms) and Mixed (both cardiomyopathy and polyneuropathy symptoms) subsets, but not the cardiomyopathy subset of the hATTR patient population. Nevertheless, given the impressive efficacy seen in the Phase 3 APOLLO trial, we expect the drug to be an attractive and competitive option for PN +Mixed patients. Reiterate BUY. Our enthusiasm for the stock is still primarily driven by the RNAi platform, which we expect to produce several more differentiated drugs going forward.””
  • 8/13/2018 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $123.00 price target on the stock, down previously from $125.00.
  • 8/13/2018 – Alnylam Pharmaceuticals was downgraded by analysts at Goldman Sachs Group Inc from a “conviction-buy” rating to a “buy” rating.

ALNY stock opened at $80.99 on Thursday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $80.00 and a twelve month high of $153.99. The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.22 and a current ratio of 13.22. The company has a market capitalization of $8.81 billion, a PE ratio of -14.94 and a beta of 2.56.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.63) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.74) by $0.11. The company had revenue of $29.91 million during the quarter, compared to the consensus estimate of $16.96 million. Alnylam Pharmaceuticals had a negative return on equity of 38.09% and a negative net margin of 533.52%. Alnylam Pharmaceuticals’s revenue was up 87.8% on a year-over-year basis. During the same period last year, the business posted ($1.07) earnings per share. Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -7.26 EPS for the current fiscal year.

In related news, COO Yvonne Greenstreet sold 2,500 shares of the stock in a transaction that occurred on Thursday, August 30th. The stock was sold at an average price of $120.00, for a total transaction of $300,000.00. Following the completion of the sale, the chief operating officer now directly owns 1,916 shares of the company’s stock, valued at $229,920. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO John Maraganore sold 50,000 shares of the stock in a transaction that occurred on Wednesday, July 25th. The shares were sold at an average price of $105.39, for a total value of $5,269,500.00. Following the sale, the chief executive officer now directly owns 201,297 shares of the company’s stock, valued at $21,214,690.83. The disclosure for this sale can be found here. Company insiders own 3.70% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of ALNY. Point72 Asset Management L.P. increased its position in shares of Alnylam Pharmaceuticals by 921.6% during the first quarter. Point72 Asset Management L.P. now owns 908,046 shares of the biopharmaceutical company’s stock valued at $108,148,000 after acquiring an additional 819,160 shares during the last quarter. American Century Companies Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $42,128,000. Baillie Gifford & Co. increased its position in shares of Alnylam Pharmaceuticals by 10.4% during the second quarter. Baillie Gifford & Co. now owns 4,231,881 shares of the biopharmaceutical company’s stock valued at $416,798,000 after acquiring an additional 397,668 shares during the last quarter. Legal & General Group Plc increased its position in shares of Alnylam Pharmaceuticals by 227.4% during the first quarter. Legal & General Group Plc now owns 348,570 shares of the biopharmaceutical company’s stock valued at $41,515,000 after acquiring an additional 242,098 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. increased its position in Alnylam Pharmaceuticals by 333.0% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 302,695 shares of the biopharmaceutical company’s stock worth $29,812,000 after buying an additional 232,782 shares during the last quarter. 93.41% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.

Read More: Risk Tolerance and Your Investment Decisions

Receive News & Ratings for Alnylam Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply